Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03639935 · ClinicalTrials.gov registry record · Phase 2
Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT03639935 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 32 participants.
The verdict
NCT03639935, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
Investigators hypothesize that following first-line platinum based chemotherapy, rucaparib in combination with nivolumab, will improve progression-free survival and overall survival in BTC patients.
Interventions
- DRUG Nivolumab
- DRUG Rucaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2019-03-28 |
| Est. Completion | 2024-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03639935
The ClinicalTrials.gov registry entry for NCT03639935 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03639935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03639935 about?
NCT03639935 is a clinical study titled "Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy". Investigators hypothesize that following first-line platinum based chemotherapy, rucaparib in combination with nivolumab, will improve progression-free survival and overall survival in BTC patients.
What is the current status of trial NCT03639935?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2019-03-28. Estimated completion is 2024-04-30.
What interventions are being tested in trial NCT03639935?
The interventions under investigation include: Nivolumab (DRUG), Rucaparib (DRUG).
Who is sponsoring clinical trial NCT03639935?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.